By Lisa Kerner
Erie, Pa., Feb. 3 - CureVac GmbH said it will receive €22 million in private funding from SAP founder Dietmar Hopp through his investment companies DH Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG.
Proceeds from the funding will be used primarily for all phases of a clinical trial for RNActiveTM in various types of carcinoma.
CureVac is a Tüebingen, Germany-based biopharmaceutical company focusing on the development of drugs to combat cancer.
| Issuer: | CureVac GmbH
|
| Issue: | Private funding
|
| Amount: | €22 million
|
| Investors: | DH Capital GmbH & Co. KG and OH Beteiligungen GmbH und Co. KG
|
| Announcement date: | Feb. 3
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
